The present invention relates to a biomarker composition for diagnosing or predicting prognosis of hepatocellular carcinoma, comprising human cytochrome P450 4A (CYP4A) as an active ingredient. More specifically, it has been confirmed that the gene and protein expression of human CYP4A in the liver tissue of the tumor part of hepatocellular carcinoma patients was significantly reduced compared to the liver tissue of a non-tumor part. As the stage of hepatocellular carcinoma progressed, the expression of human CYP4A decreased, and the lower the expression of human CYP4A, the higher the possibility of recurrence of hepatocellular carcinoma and the lower the patient survival rate. Therefore, human CYP4A is available as a biomarker of hepatocellular carcinoma, and the human CYP4A expression rate analysis is expected to be useful for the prevention or treatment of hepatocellular carcinoma by developing a composition for diagnosing or predicting prognosis of hepatocellular carcinoma.
展开▼
